Also, a direct effect of anti-IL17 inhibitors in obesity is not clearly documented and this is rather troubling for those promoting the hypothesis suggesting that anti-IL17 neutralizing antibodies may indeed have a clinical impact in fighting obesity. The gene discussed is IL17A; the disease is obesity due to melanocortin 4 receptor deficiency.